Utilization and Treatment Costs of Tumor Necrosis Factor Inhibitors After the Introduction of Biosimilar Infliximab in the United States

2020 ◽  
Vol 72 (6) ◽  
pp. 1036-1038 ◽  
Author(s):  
Seoyoung C. Kim ◽  
Ameet Sarpatwari ◽  
Joan E. Landon ◽  
Rishi J. Desai
2011 ◽  
Vol 15 (2) ◽  
pp. 264-275 ◽  
Author(s):  
Vernon F. Schabert ◽  
Crystal Watson ◽  
Shravanthi R. Gandra ◽  
Seth Goodman ◽  
Kathleen M. Fox ◽  
...  

2014 ◽  
Vol 2014 ◽  
pp. 1-4 ◽  
Author(s):  
Uzoamaka A. Eke ◽  
Harry Conte ◽  
Paula Anderson ◽  
Robert W. Lyons

Salmonella choleraesuisis one of the least commonly reported nontyphoidal salmonellae in the United States, accounting for only 0.08% and ranking lower than 20th place among all human source salmonellosis reported to the CDC in 2009. In the state of Connecticut, only 12 cases have been reported since 1998 and our case is the only case since 2008. We report a case of invasive Salmonellosis caused bySalmonella choleraesuisin a patient on an antitumor necrosis factor-αagent (adalimumab) who recently returned from a trip to the Dominican Republic.


2006 ◽  
Vol 73 (6) ◽  
pp. 718-724 ◽  
Author(s):  
Khalid M. Kamal ◽  
S. Suresh Madhavan ◽  
Jo Ann Allen Hornsby ◽  
Lesley-Ann Miller ◽  
Jan Kavookjian ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document